[go: up one dir, main page]

NO20075186L - Substituerte glycinamider som har antitrombotisk og faktor XA-inhiberende effekt. - Google Patents

Substituerte glycinamider som har antitrombotisk og faktor XA-inhiberende effekt.

Info

Publication number
NO20075186L
NO20075186L NO20075186A NO20075186A NO20075186L NO 20075186 L NO20075186 L NO 20075186L NO 20075186 A NO20075186 A NO 20075186A NO 20075186 A NO20075186 A NO 20075186A NO 20075186 L NO20075186 L NO 20075186L
Authority
NO
Norway
Prior art keywords
antithrombotic
factor
inhibitory effect
substituted glycinamides
glycinamides
Prior art date
Application number
NO20075186A
Other languages
English (en)
Other versions
NO340670B1 (no
Inventor
Wolfgang Wienen
Henning Priepke
Kai Gerlach
Roland Pfau
Annette Maria Schuler-Metz
Georg Dahmann
Herbert Nar
Sandra Ruth Handschuh
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20075186L publication Critical patent/NO20075186L/no
Publication of NO340670B1 publication Critical patent/NO340670B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det beskrives nye substituerte glycinamider med den generelle formel (I) hvor D, M, R3, R4 og R5 er definert som angitt i beskrivelsen, deres tautomerer, enantiomerer, diastereomerer, blandinger og salter, spesielt deres fysiologisk akseptable salter med uorganiske eller organiske syrer eller baser, som oppviser verdifulle egenskaper.
NO20075186A 2005-06-30 2007-10-11 Substituerte glycinamider, farmasøytiske blandinger inneholdende slike samt fremagangsmåte for fremstilling av disse. NO340670B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05014270 2005-06-30
PCT/EP2006/063611 WO2007003536A1 (de) 2005-06-30 2006-06-28 Substituierte glycinamide mit antithrombotischer und faktor xa-inhibierender wirkung

Publications (2)

Publication Number Publication Date
NO20075186L true NO20075186L (no) 2008-02-14
NO340670B1 NO340670B1 (no) 2017-05-29

Family

ID=35907001

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075186A NO340670B1 (no) 2005-06-30 2007-10-11 Substituerte glycinamider, farmasøytiske blandinger inneholdende slike samt fremagangsmåte for fremstilling av disse.

Country Status (32)

Country Link
US (3) US20100216769A1 (no)
EP (1) EP1899330B9 (no)
JP (1) JP4768016B2 (no)
KR (1) KR101321722B1 (no)
CN (1) CN101213195B (no)
AR (1) AR054627A1 (no)
AT (1) ATE489381T1 (no)
AU (1) AU2006265216B2 (no)
BR (1) BRPI0612580A8 (no)
CA (1) CA2613059C (no)
CY (1) CY1111627T1 (no)
DE (1) DE502006008392D1 (no)
DK (1) DK1899330T3 (no)
EA (1) EA015188B1 (no)
EC (1) ECSP078058A (no)
ES (1) ES2357029T3 (no)
HR (1) HRP20110044T2 (no)
IL (1) IL188323A (no)
MX (1) MX2007016253A (no)
MY (1) MY145883A (no)
NO (1) NO340670B1 (no)
NZ (1) NZ565440A (no)
PE (1) PE20070171A1 (no)
PL (1) PL1899330T3 (no)
PT (1) PT1899330E (no)
RS (1) RS51572B (no)
SG (1) SG163540A1 (no)
SI (1) SI1899330T1 (no)
TW (1) TWI392495B (no)
UA (1) UA94910C2 (no)
WO (1) WO2007003536A1 (no)
ZA (1) ZA200708525B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459448B2 (en) 2004-10-04 2008-12-02 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
CA2692440A1 (en) * 2006-07-20 2008-01-24 Cascade Therapeutics Inc. Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands
PE20081834A1 (es) * 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
EP2220079A2 (en) * 2007-11-15 2010-08-25 Boehringer Ingelheim International GmbH Substituted amides, manufacturing and use thereof as medicaments
JP5562865B2 (ja) 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
AR074487A1 (es) 2008-12-05 2011-01-19 Millennium Pharm Inc Tiolactamas inhibidoras de proteinquinasas plk, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de trastornos proliferativos e inflamatorios, en particular cancer.
EP2398781A1 (en) * 2009-02-17 2011-12-28 Msd K.K. 1,4-benzodiazepin-2-on derivatives
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
CN108641002A (zh) 2012-12-18 2018-10-12 西奈山伊坎医学院 流感病毒疫苗及其用途
EP3102200B1 (en) * 2014-02-07 2023-04-05 Exithera Pharmaceuticals Inc. Therapeutic compounds and compositions
CN105622511B (zh) * 2014-11-03 2018-01-23 北京瑞都医药科技有限公司 一种减肥药物及其制备方法
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
MA53089B1 (fr) 2018-07-05 2022-11-30 Bayer Ag Thiophènecarboxamides substitués et analogues comme agents antibactériens
CN111196772B (zh) * 2018-11-16 2022-09-30 沈阳化工研究院有限公司 一种芳酰氨基异丁酰衍生物及其应用
HUE068308T2 (hu) 2019-12-20 2024-12-28 Bayer Ag Tieniloxazolonok és analógok
JP7502564B2 (ja) 2020-11-06 2024-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２－［（チオフェン－２－イル）ホルムアミド］－ｎ－（フェニル）－２－メチルプロパンアミド誘導体及びその医薬としての使用
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855715B1 (en) 1999-06-14 2005-02-15 Eli Lilly And Company Serine protease inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
EA005893B1 (ru) * 2000-03-21 2005-06-30 Смитклайн Бичам Корпорейшн Ингибиторы протеаз
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
EP1401453A4 (en) 2001-05-17 2005-04-06 Smithkline Beecham Corp PROTEASE INHIBITORS
US20060223826A1 (en) 2002-11-19 2006-10-05 Takeda Pharmaceutical Company Limited Intellectual Property Department Indole derivatives as somatostatin agonists or antagonists
JP2004300133A (ja) * 2002-11-19 2004-10-28 Takeda Chem Ind Ltd アミン誘導体
DE10254336A1 (de) 2002-11-21 2004-06-03 Merck Patent Gmbh Carbonsäureamide
US7250415B2 (en) 2003-06-04 2007-07-31 Bristol-Myers Squibb Company 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors
EP1748997A1 (de) 2004-05-13 2007-02-07 Boehringer Ingelheim International Gmbh Substituierte thiophen-2-carbonsäureamide, deren herstellung und deren verwendung als arzneimittel
EP1747217A1 (de) * 2004-05-13 2007-01-31 Boehringer Ingelheim International GmbH Neue substituierte thiophencarbonsäureamide, deren herstellung und deren verwendung als arzneimittel
EP1748996A1 (de) * 2004-05-13 2007-02-07 Boehringer Ingelheim International GmbH Substituierte thiophencarbonsäureamide, deren herstellung und deren verwendung als arzneimittel
DE102004047840A1 (de) * 2004-09-29 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
PE20081834A1 (es) 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos

Also Published As

Publication number Publication date
CN101213195B (zh) 2012-05-09
PT1899330E (pt) 2011-01-11
IL188323A0 (en) 2008-04-13
CN101213195A (zh) 2008-07-02
DE502006008392D1 (de) 2011-01-05
WO2007003536A1 (de) 2007-01-11
US20100216769A1 (en) 2010-08-26
TW200738692A (en) 2007-10-16
EP1899330B9 (de) 2011-11-09
PL1899330T3 (pl) 2011-05-31
IL188323A (en) 2013-08-29
TWI392495B (zh) 2013-04-11
AU2006265216A1 (en) 2007-01-11
KR20080033318A (ko) 2008-04-16
BRPI0612580A8 (pt) 2017-12-26
BRPI0612580A2 (pt) 2010-11-23
ES2357029T3 (es) 2011-04-15
JP4768016B2 (ja) 2011-09-07
AU2006265216B2 (en) 2011-09-29
MY145883A (en) 2012-05-15
US9062034B2 (en) 2015-06-23
UA94910C2 (ru) 2011-06-25
US20130184256A1 (en) 2013-07-18
ATE489381T1 (de) 2010-12-15
EA015188B1 (ru) 2011-06-30
US20150252050A1 (en) 2015-09-10
SG163540A1 (en) 2010-08-30
DK1899330T3 (da) 2011-02-21
NZ565440A (en) 2011-04-29
JP2008546741A (ja) 2008-12-25
ZA200708525B (en) 2009-08-26
SI1899330T1 (sl) 2011-03-31
EP1899330A1 (de) 2008-03-19
HRP20110044T2 (hr) 2012-02-29
EP1899330B1 (de) 2010-11-24
AR054627A1 (es) 2007-07-04
HK1116190A1 (en) 2008-12-19
HRP20110044T1 (hr) 2011-02-28
EA200702620A1 (ru) 2008-06-30
CA2613059A1 (en) 2007-01-11
CY1111627T1 (el) 2015-10-07
US9676781B2 (en) 2017-06-13
RS51572B (sr) 2011-08-31
NO340670B1 (no) 2017-05-29
MX2007016253A (es) 2008-03-07
KR101321722B1 (ko) 2013-10-25
ECSP078058A (es) 2008-01-23
CA2613059C (en) 2013-12-24
PE20070171A1 (es) 2007-03-08

Similar Documents

Publication Publication Date Title
NO20075186L (no) Substituerte glycinamider som har antitrombotisk og faktor XA-inhiberende effekt.
NO20064003L (no) Nyekarboksamider for anvendelse som XA-inhibitorer
NO20084530L (no) Substituerte prolinamider, deres produksjon og anvendelse som medikament
NO20091025L (no) Arylsulfonamider med analgesisk virkning
WO2009065919A3 (de) Organische verbindungen
WO2009065920A3 (de) Verbindungen
NO20070445L (no) Pyrimidinderivater.
NO20093200L (no) Tiazolidinderivater
TNSN07272A1 (en) Substituted bis aryl and heteroaryl compounds as selective 5ht 2a antagonists
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
WO2009046841A3 (de) Piperidin- und piperazinderivate zur behandlung von tumoren
NO20082388L (no) Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer
NO20083669L (no) 4-aryl-2amino-pyrimidiner eller 4-aryl-2-aminoalkylpyrimidiner som jak-2-modulatorer og fremgangsmater for anvendelse derav
NO20064599L (no) Substituerte morfolin- og tiomorfolinderivater
NO20023161L (no) Substituerte piperidiner, legemidler inneholdende disse forbindelser og fremgangsmåter for fremstilling av dem
NO20054340L (no) Nye sammenkoplede heterocykler og deres anvendelse
NO20073941L (no) Dihydroimidazotiazolderivater
MY148769A (en) Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments
NO20070089L (no) DPP-IV inhibitorer
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
WO2009034029A3 (de) 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten
NO20070148L (no) Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen
WO2008135525A3 (en) Substituted azetidines, manufacturing and use thereof as medicaments
TW200738693A (en) Substituted biaryls, process for their manufacture and use thereof as medicaments
NO20076396L (no) Substituert akrylamidderivat og farmasoytisk preparat som omfatter dette

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees